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Background: Circulating tumour cells (CTCs) have shown prognostic relevance in metastatic breast, prostate, colon
and pancreatic cancer. For further development of CTCs as a biomarker, we compared the performance of different
protocols for CTC detection in murine breast cancer xenograft models (MDA-MB-231, MDA-MB-468 and KPL-4).
Blood samples were taken from tumour bearing animals (20 to 200 mm2) and analysed for CTCs using 1. an
epithelial marker based enrichment method (AdnaTest), 2. an antibody independent technique, targeting human
gene transcripts (qualitative PCR), and 3. an antibody-independent approach, targeting human DNA-sequences
(quantitative PCR). Further, gene expression changes associated with epithelial-to-mesenchymal transition (EMT)
were determined with an EMT-specific PCR assay.
Methods: We used the commercially available Adna Test, RT-PCR on human housekeeping genes and a PCR on
AluJ sequences to detect CTCs in xenografts models. Phenotypic changes in CTCs were tested with the
commercially available “Human Epithelial to Mesenchymal Transition RT-Profiler PCR Array”.
Results: Although the AdnaTest detects as few as 1 tumour cell in 1 ml of mouse blood spiking experiments, no
CTCs were detectable with this approach in vivo despite visible metastasis formation. The presence of CTCs could,
however, be demonstrated by PCR targeting human transcripts or DNA-sequences - without epithelial pre-
enrichment. The failure of CTC detection by the AdnaTest resulted from downregulation of EpCAM, whereas
mesenchymal markers like Twist and EGFR were upregulated on CTCs. Such a change in the expression profile
during metastatic spread of tumour cells has already been reported and was linked to a biological program termed
epithelial-mesenchymal transition (EMT).
Conclusions: The use of EpCAM-based enrichment techniques leads to the failure to detect CTC populations that
have undergone EMT. Our findings may explain clinical results where low CTC numbers have been reported even
in patients with late metastatic cancers. These results are a starting point for the identification of new markers for
detection or capture of CTCs, including the mesenchymal-like subpopulations.
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Metastasis is a multistep process in the course of which
tumour cells migrate into the circulation, generating circu-
lating tumour cells (CTCs) in the blood stream or dissemi-
nated tumour cells (DTCs) that home to the bone marrow
[1]. It is thought that epithelial tumour cells have to
undergo phenotypic changes to overcome the successive
barriers to intravasation, survival in the blood, extravasa-
tion and secondary tumour formation [2]. These changes
are accompanied by a reduction of cell-cell adhesion, loss
of apical-basolateral polarity, and loss of epithelial marker
expression whereas the expression of mesenchymal-
associated genes is induced [3]. This developmental pro-
gram, described as epithelial-to-mesenchymal transition
(EMT), may be a prerequisite for invasive growth and
metastatic spread [4]. Although the role of EMT for CTCs
is still under debate, recent findings support the hypothesis
that CTC profile changes occur during tumour cell dis-
semination [5-7]. As EMT processes in human samples are
hard to follow and because of the difficulty of detecting
CTCs in humans [8], animal models could help to evaluate
and dissect the functional implications of EMT specific
processes in vivo.
CTCs could already be detected in blood samples of an
orthotopic breast cancer model (MDA-MB-231) using a
modified version of the FDA approved CellSearch tech-
nique [9]. In xenograft models of prostate cancer, however,
CTCs could only be detected after a second round of
tumour cell inoculation after one in vivo passage [10].
CTCs isolated from MDA-MB-231 breast cancer xeno-
grafts display a more aggressive phenotype than the ori-
ginal cells, indicating the impact of CTCs for metastatic
formation [11]. In addition, phenotypic changes on CTCs
in animal models were also demonstrated [12], showing
that CTCs are technically suitable for functional character-
isation. We compared different breast cancer models
(MDA-MB-231, MDA-MB-468 and KPL-4) in order to test
their suitability to serve as model system for CTC forma-
tion. The fast emergence of mesenchymal-related CTC
populations led to identification of new markers for CTC
detection.Methods
Cell culture
Human breast cancer cell lines MDA-MB-231 (ECACC,
#92020424), MDA-MB-468 (ATCC, #HTB-132) and
KPL-4 (Kawasaki Medical School) were cultured in
DMEM/F12 + 200 mM glutamine (MDA-MB-231,
MDA-MB-468) or RPMI+Glutamax (KPL-4) supple-
mented with 10% fetal calf serum (FCS) and 1% penicil-
lin/streptomycin. Cells were maintained at 37°C in a
humidified incubator with 5% CO2. Adherent cells were
harvested at 80% confluency by washing with sterileDulbecco’s phosphate buffered saline (PBS) followed by
trypsinisation for 5 min at 37°C.
Western blot
For the detection of EpCAM (epithelial cell adhesion mol-
ecule) and MUC-1 (mucin-1) expression, Western Blot
analysis was performed. 20 μg of total cell protein were
separated using SDS polyacrylamide gel electrophoresis
(SDS-PAGE), and proteins were transferred to a nitrocellu-
lose membrane. The membrane was blocked with PBS
containing 0.1% Tween-20 (PBS-T) and 5% skimmed milk
powder for 1 h at room temperature (RT). Following the
blocking step, the EpCAM (abcam; [E144] (ab32392), 1 :
100) and MUC-1 (abcam; [EP1024Y] (ab45167), 1 : 1,000)
primary antibodies were added and incubated over night at
4°C. The blot was washed three times with PBS-T. Next,
horseradish peroxidase-conjugated secondary antibody was
added to the blocking solution (GE Healthcare: NIF824, 1 :
5,000) and incubated for 2 h at RT. After three washing
steps with PBS-T, detection was carried out using Amer-
sham ECL Western Blotting Systems (RPN2232) and Ima-
gequant software. Tubulin (Sigma: T6074, 1:2000)
detection was included as loading control. The secondary
antibody was purchased from GE Healthcare (NA93IVS).
Flow cytometry
5 x 105 cells were detached by trypsinisation, washed and
stained for 30 min at RT in the dark. For the analysis of
EpCAM expression tumour cells were stained with an
APC-labeled (allophycocyanin) anti-EpCAM antibody (BD
Bioscience, Cat. no. 347200; 1:200). FACS (fluorescence
activated cell sorting) analysis was performed (FACScali-
bur) with addition of SYTOXW Red Dead Cell Stain (Invi-
trogen, Cat. No. S34859) to exclude dead cells. 10,000 cells
were counted for the analysis.
AdnaTest system
The AdnaTest System is a method based on immuno-
magnetic enrichment of epithelial tumour cells using
antibodies against EpCAM and MUC-1 followed by
mRNA isolation via oligo(dT)-conjugated magnetic par-
ticles for the analysis of tumour associated gene expres-
sion by RT-PCR (EpCAM, MUC-1, Her2 (human
epithelial growth factor receptor 2), and Actin). This
assay was developed for the detection of CTCs in 5 ml
of human blood. Since much smaller amounts of blood
can be collected from murine models (800 to 1,000 μl,
or ~1/5 of the recommended blood volume), we reduced
the BreastSelect Beads (BreastCancerSelect, Article no.
T-1-508) to 25 μl instead of 100 μl per sample. The rest
of the protocol was carried out according to the manu-
facturer’s instructions. In the PCR reaction (run on a
Veriti Thermal Cycler, Applied Biosystems), amplicons
of the following sizes were generated: EpCAM: 395 base
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114 bp. Visualisation of the PCR products was carried
out with a 2100 Bioanalyser using DNA 1000 LabChips
(Agilent Technologies), as recommended by AdnaGen.
Qualitative CTC detection - targeting human gene
transcripts
100 μl blood samples were collected from mice in EDTA-
tubes (S-Monovette, Sarstedt) and transferred to RNApro-
tect Animal Blood Tubes (Qiagen Cat. No. 76544) for
immediate stabilisation of cellular RNA. Next, total RNA was
purified using the RNeasy Protect Animal Blood Kit (Qia-
gen, Cat. No. 73224). cDNA synthesis was performed with
800 ng of RNA using the High Capacity RNA-to-cDNA
Kit from Applied Biosystems (Cat. No. 4387406). For CTC
detection, we designed human-specific primers targeting
mRNA of the housekeeping genes glycerinaldehyd-
3-phosphat-dehydrogenase (GAPDH) [Fwd 5`-
ATCATCCCTGCCTCTACTGG-3`/Rev 5`-GTCAGGTC-
CACCACTGACAC-3`] and peptidylprolyl isomerase A
(PPIA) [Fwd 5`-TTCATCTGCACTGCCAAGAC-3`/Rev
5`-TCGAGTTGTCCACAGTCAGC-3`] and the mesenchy-
mal marker Vimentin [Fwd 5`-CGAAAACACCCTG-
CAATCTT-3`/Rev 5`-TCCAGCAGCTTCCTGTAGGT-3`].
PCR Master Mix was prepared by mixing 5 μl cDNA to-
gether with 12.5 μl HotStarTaq Master Mix Kit (Qiagen,
Cat. No. 203443, 250 U). Primers were added to a final
concentration of 0.5 μM and the samples were filled up
with RNase-free water to a total volume of 25 μl. Add-
itional amplifications with 2 μl of the BreastDetect primer
mix from the AdnaTest (BreastDetect, Adna Article no. T-
1-509) were performed to analyse EpCAM, MUC-1 and
Her2 gene expression. PCR was performed under the fol-
lowing conditions: after 15 min denaturation at 95°C, 42
cycles were carried out by denaturation at 94°C for 40 s,
annealing/extension at 60°C for 40 s and elongation for 30
to 60 s at 72°C. A final elongation step at 72°C for 10 min
was followed by storage of the samples at 4°C. The PCR
generates products of the following sizes: Vimentin:
618 bp, EpCAM, MUC-1 and Her2 (as mentioned before),
GAPDH: 138 bp, and PPIA: 133 bp. Visualisation was done
with a Agilent 2100 Bioanalyser and peaks with a concen-
tration above 1 ng/μl were defined as positive (Agilent
Assay properties: normal). The actin primers of the
AdnaTest could not be evaluated in this setting since they
are not human-specific.
Quantitative CTC detection - targeting human
DNA (alu-sequences)
200 μl of murine blood were collected and red blood cells
were lysed using RBC lysis solution from Qiagen for
10 min at 4°C (Cat. No. 158904). Next, samples were cen-
trifuged for 10 min (450 g), followed by two washing steps
using 1 ml of sterile PBS. DNA isolation was performedusing DNeasy Mini Kits (Qiagen, Cat. No. 51306). 5 μl of
the eluate were taken for qRT-PCR targeting human Alu-
sequences [For 5`- CACCTGTAATCCCAGCACTTT-3
`/Rev 5`-CCCAGGCTGGAGTGCAGT-3`] [13]. Primers
were added to a final concentration of 0.5 μM and the
samples were filled up with RNase free water to a total vol-
ume of 25 μl. PCR (Real-Time PCR System 7500, Applied
Biosystems) using the QuantiTec SYBR Green PCR Kit
(Qiagen, Cat. No. 204143) was done as follows: after
15 min denaturation at 95°C, 40 cycles were carried out by
denaturation at 94°C for 60 s, annealing/extension at 60°C
for 30 s and elongation for 30 at 72°C. Amplification
curves were analysed and the number of CTCs were calcu-
lated by spiking experiments which were included in every
run. DNA from murine blood and water were included as
negative controls.
Spiking experiments
Spiking experiments were done to test the sensitivity of
the different methods. Fresh EDTA-blood was collected
from female athymic NCr nude mice (nu/nu; Taconic).
Cultured cells were harvested by trypsinisation and
spiked into 1 ml of murine blood for the AdnaTest or
100 to 200 μl for detection of CTCs without antibody
pre-enrichment. 1 to 50 cells were collected by pipetting
under microscopic control, whereas higher numbers
(1,000 and 100,000 cells) were prepared by dilution
series. As negative controls, 20 murine blood samples
were tested for each approach.
Murine xenografts
5 to 6 week old female NCr nude mice were used through-
out all xenograft studies. All experiments were approved
by the local regulatory agency Landesamt für Gesundheit
und Soziales Berlin (approval number: 1403). Mice were
housed according to institutional guidelines with highest
animal welfare standards [14]. For in vivo inoculation, har-
vested cells were counted with a CASY DT Cell Counter
and Analyser (Innovatis AG). Cell number and viability
were determined using the Analyser Software. Cells were
kept at 4°C and resuspended in cold PBS or mixed with
Matrigel (1 : 1) (BD Biosciences). 1 x 105 to 2 x 106 viable
cells (MDA-MB-231, -468, and KPL-4) were injected
orthotopically into mammary fat pads (m.f.p.) of the mice
in a volume of 50 μl. Subsequently, mice were monitored
for tumour growth.
Alternatively, for testing the stability of marker expres-
sion in CTCs, 1 x 105 to 5 x 105 cells of the KPL-4 and
MDA-MB-231 line were injected into the tail vein or into
the heart of female nude mice in a volume of 150 μl PBS.
Blood collection and autopsy
We obtained EDTA-blood from either the jugular vein,
the inferior vena cava or by cardiac puncture as tumours
Gorges et al. BMC Cancer 2012, 12:178 Page 4 of 13
http://www.biomedcentral.com/1471-2407/12/178reached sizes between 20 to 200 mm2. Tumours, lymph
nodes, lungs and livers were taken out and immediately
frozen in liquid nitrogen for the detection of metastases
by PCR of human transcripts.
RNA isolation and mRNA amplification from tumours
and tissues
Tissue was homogenised using Lysing Matrix D (MP Bio-
medicals, Cat. No. 116913500) and Fast Prep-24 System
(MP Biomedicals, Cat. No. 116003500). RNA was purified
using the RNeasy Mini Kit from Qiagen (Cat. no. 74104)
and cDNA synthesis was performed with 400 ng of RNA
input using the High Capacity RNA-to-cDNA Kit. PCR
Master Mix was prepared as followed: 4 μl cDNA, 12.5 μl
HotStarTaq Master Mix Kit and 2 μl of the primers from
the AdnaTest kit or 0.5 μM in case of GAPDH, PPIA and
vimentin. Each sample was filled up to 25 μl with RNase
free water. Again, actin was excluded from analysis as sig-
nals were obtained in lysed tissues of tumour-free mice
(data not shown). The Thermocycler was used for the
PCR. Conditions were chosen as follows: 15 min denatur-
ation at 95°C, 40 cycles of PCR were carried out by de-
naturation at 94°C for 40 s, annealing at 60°C for 40 s and
elongation for 60 s at 72°C. Subsequently, termination of
the reaction was carried out at 72°C for 10 min followed
by storage of the samples at 4°C. 20 tumour-free (naive)
mice were analysed as negative controls. Visualisation was
done with an Agilent 2100 Bioanalyser and peaks with a
concentration above 1 ng/μl were defined as positive
(Assay properties set to “normal”).
Gene expression analysis of CTCs
EMT-like changes on CTCs during tumour growth were
analysed in orthotopic models using the “Human Epithelial
to Mesenchymal Transition RT-Profiler PCR Array” Sys-
tem (SABiosciences, Cat. No: PAHS-090 C). This array
profiles the expression of 84 genes that have been asso-
ciated with EMT. 500 μl of blood were collected and trans-
ferred to RNAprotect Animal Blood Tubes. Total RNA
was purified using the RNeasy Protect Animal Blood Kit
and cDNA synthesis was performed using the RT2 First
Strand Kit (SABiosciences, Cat. No. C-03/330401). A pre-
amplification step was included using the PreAMP cDNA
Synthesis Primer Mix (SABiosciences Cat. No. PBH-9090).
Next, sample cocktails were loaded onto the array and
amplification was performed as recommended by the
vendor. Two murine blood samples were included as nega-
tive controls to test the species specificity of the assay. Al-
though the array is intended to be human specific, only 14
genes could be included for data analysis in our study since
mRNA signals for the remaining 70 genes were detected in
blood samples from control mice. Genes with a cycle
threshold (Ct) value below 36 in the control setting were
excluded from expression analysis. As positive control, 10cells of the KPL-4 cell line with epithelial phenotype were
spiked into 500 μl of native blood. ΔCt values were calcu-
lated by subtracting the Ct value of the target gene from
the Ct value of the house-keeping gene (GAPDH). ΔCt
values of blood samples taken from tumour-bearing ani-
mals (KPL-4, n=5) were subtracted from ΔCt values of the
epithelial control (ΔΔCt). Negative ΔΔCt (relative quantifi-
cation) values represent upregulated genes whereas posi-
tive values indicate downregulation of the markers.
Results
Detection of CTCs using the AdnaTest
To establish sensitivity and specificity of the AdnaTest
System, 1 to 50 cells of human breast cancer cell lines
MDA-MB-231, MDA-MB-468, and KPL-4 were spiked
into 1 ml of blood collected from tumour-free mice. We
could detect as few as 1 human cancer cell/1 ml blood
when spiking cells of the MDA-MB-468 and KPL-4 line,
which express high levels of EpCAM. In contrast, the
detection limit for EpCAMlow cells (MDA-MB-231) was
reached at 10 cells/ml (Figure 1a - c). We conclude that
the detection limit of this assay is dependent on the
EpCAM expression, since comparable MUC-1 RNA
levels were detected in all three cell lines by a faint band
in the samples containing 10 spiked cells (Figure 1a) and
more relevant, similar protein expression levels were
observed in all three cell lines (Figure 1c). Analysis of
non-spiked blood samples revealed no positive signal,
confirming the specificity of the assay.
Having validated the threshold, we next tried to detect
CTCs in orthotopic breast cancer models (n = 96) bear-
ing tumours of 20 to 200 mm2 in size (MDA-MB-231,
MDA-MB-468 and KPL-4). To analyse possible meta-
static spread, draining lymph nodes (axillary: LN1), re-
mote lymph nodes (inguinal: LN2), lungs and livers were
analysed for the presence of human mRNA. Such evi-
dence for metastases was found in nearly all xenografted
animals. The lymph nodes located next to the primary
tumour or the lungs were infiltrated first during tumour
growth (Figure 2a) and with increasing tumour size, me-
tastases in livers and distant lymph nodes became visible
as well. Most of the primary tumours and metastases
were positive for EpCAM, MUC-1 and Her2 but in
some cases, EpCAM and especially MUC-1 expression
disappeared (Figure 2a - d). Despite extensive tumour
vascularisation (Figure 2e) and metastatic spread, the
AdnaTest system revealed no positive signal for CTCs in
blood of any sample collected from jugular vein, inferior
vena cava or by cardiac puncture (Figure 2a - d).
CTC detection without pre-enrichment
We hypothesised that phenotypic changes associated
with the epithelial-to-mesenchymal transition (EMT)
and downregulation of the epithelial surface marker
Figure 1 (See legend on next page)
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Figure 1 a. Breast cancer cell detection by the AdnaTest - ex vivo. Tumour cells were spiked into 1 ml of fresh mouse blood. Signals for
human mRNA of EpCAM, MUC-1, Her2 and Actin were detected at different thresholds for each cell line. No false positive results were seen in
control blood samples without human breast cancer cells. Negative controls without mRNA input were performed to exclude false positive
results (“RT-“). Positive control was included in the AdnaTest Kit (“PCR+”). b. FACS analysis for EpCAM expression. Breast cancer cells were
analysed by fluorescence activated cell sorting for EpCAM expression. Unstained cells are shown in the upper panels. Cells of the MDA-MB-231
line show very weak signals for EpCAM expression compared to MDA-MB-468 and especially cells of the KPL-4 line. c. Western Blot analysis for
EpCAM and MUC-1 expression . Cells of the MDA-MB-231 line show weak signals for EpCAM expression compared to MDA-MB-468 and
KPL-4 cells, whereas comparable MUC-1 expression levels are seen. Tubulin detection was performed as loading control.
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CTCs using the AdnaTest. Therefore, we established two
EpCAM-independent methods for CTC detection. The
methods were based either on mRNA amplification of
human gene transcripts (GAPDH, PPIA, EpCAM,
MUC-1, Her2 and Vimentin) or amplification of human
DNA (Alu-sequences).
One to 10,000 human breast cancer cells (MDA-MB-
231, MDA-MB-468 and KPL-4) were spiked into the
blood of naive mice for assay validation. No false posi-
tive result was seen in blood from tumour-free controlFigure 2 Metastases and blood analysis of xenografted and tumour-f
mice (a). Metastatic formation was seen in all xenografts. Most of the prima
and Her2 expression but downregulation of EpCAM and mainly MUC-1 wa
detected by the AdnaTest in the blood of any murine xenograft although
these mice (a-f).mice (n = 20), proving that the used PCR primers were
specific to human sequences and therefore did not give
any background signals, for example for Vimentin that
would be expected in mesenchymal blood cells. All
spiked samples showed positive signals for GAPDH and
PPIA. As few as 2 tumour cells in 100 μl mouse blood
could be reproducibly detected by expression of human
housekeeping genes. EpCAM signals were detectable
from 2 tumour cells or more for EpCAMhigh cells
(MDA-MB-468, KPL-4) but the detection limit was 10
tumour cells in case of EpCAMlow cells (MDA-MB-231)ree mice. No human mRNA was detectable in tissue or blood of naive
ry tumours and metastases were positive for mRNA of EpCAM, MUC-1
s observed, as well (a-d). No signals for human tumour cells could be
extensive tumour vascularisation and metastatic spread was seen in
Figure 3 Expression profile of breast cancer cells spiked into native mouse blood. RNA was isolated and cDNA synthesis was performed.
Human mRNA of Vimentin, EpCAM, MUC-1, Her2, GAPDH and PPIA was detectable at different cell numbers. No signals for murine mRNA were
seen in native blood samples.
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of the basal like MDA-MB-231 line (2 cells/100 μl) and
weakly in the MDA-MB-468 line (from 1,000 cells on)
whereas no signals for Vimentin were seen in blood
samples spiked with cells of the KPL-4 line (Figure 3).
The cells also show the described Her2 expression pat-
tern, very strong signals in KPL4 cells and very weak sig-
nals in MDA-MB-231 and MDA-MB-468.Figure 4 Quantitative detection of CTCs targeting human Alu-sequen
tumour-free murine blood. DNA was isolated and qRT-PCR was performed
detected before negative controls. Measurements were done in triplicatesFor comparison, we also tested the detection of human
cells by amplification of repetitive DNA sequences of the
AluJ type. This approach could be more robust than
testing RNA and should enable the quantification of
cells due to the fixed copy number of these sequences.
Using this approach, however, signals from 1 tumour cell
in 200 μl blood could be detected in only 5 out of 8
(60%) spiking experiments (Figure 4). Signals from 10ces. 1 to 100,000 human cancer cells were spiked into 200 μl of
targeting human Alu-sequences. As little as 1 human cell could be
(n.d. = not defined).
Figure 5 CTC detection targeting human gene transcripts. Representation of tumour growth in xenografted mice. CTCs were detectable at a
tumour size of 50 mm2 for all tested cell lines. CTCs out of blood samples were mostly negative for mRNA of EpCAM, MUC-1 and Her2 but
showed signals for housekeeping-genes and Vimentin (MDA-MB-231, KPL-4).
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samples. Thus, the higher abundance of house-keeping
gene mRNA leads to higher sensitivity of the RNA based
CTC detection.
Having validated the methods, we next tested the per-
formance of these CTC detection protocols in vivo.
Using detection of GAPDH and PPIA transcripts, CTCs
could be detected in nearly all blood samples collected
by cardiac puncture (Figure 5). Positive signals were
found in mice bearing tumours of 50 mm2 size, consist-
ent with the appearance of lymph node metastases at
this stage (Figure 2). In contrast, no signals for EpCAM,
MUC-1 or Her2 transcripts could be detected in these
samples, with the exception of one sample (Figure 5).
Vimentin expression was, however, found in blood sam-
ples of mice bearing MDA-MB-231 tumours and sur-
prisingly, in mice bearing xenografts from the KPL-4 cell
line indicating EMT-like changes in this model, since no
vimentin-specific transcripts could be detected in spik-
ing experiments using cells taken directly from cell cul-
tures (Figures 3 and 5).
Quantitative analysis revealed that blood samples con-
tain CTCs at numbers which should be sufficient for de-
tection with the AdnaTest, given that this assay detected
as few as 1 cell/ml in spiking experiments (Table 1).
Tumour cell numbers between 5 and 20 cells/ml (MDA-
MB-231 and KPL-4) could be detected by targetinghuman Alu-sequences. However, no CTCs could be
found when MDA-MB-231 cells were transplanted sub-
cutaneously (Table 1).
Phenotypic changes of CTCs after intravenous and
intracardiac injection
As we found a number of changes in gene expression
comparing cell lines grown in vitro and in xenografts,
we investigated the time course for changes in EpCAM
and MUC-1 gene expression. First, we spiked 10 cells of
the KPL-4 line into 100 μl or 1 ml of mouse blood.
30 min to 4 h later gene expression was assessed by
qualitative PCR or the AdnaTest. Spiked cells were
detected with both methods at all time points indicating
stable mRNA and protein levels of EpCAM (ex vivo)
(Figure 6a). Next, 100,000 cells of the KPL-4 line were
injected into the tail vein of female mice and blood was
collected by cardiac puncture for cell detection after
30 min to 4 h. No cells could be detected by the AdnaT-
est although 5 to 25 cells/ml were detected by amplifica-
tion of human Alu-sequences (data not shown).
Tumour cells showed dynamic changes and down-
regulated EpCAM and Her2 while circulating through
the bloodstream (Figure 6a). Interestingly, cells adhering
in the lungs kept EpCAM and Her2 mRNA expression
(Figure 6b). To confirm these findings, we injected
500,000 cells of the MDA-MB-231 line into the heart of
Table 1 Quantitative detection of CTCs in tumour bearing
animals




MDA-MB-231 50 mm2 0/5
(orthotopic) (5)
MDA-MB-231 80 mm2 3/5
(orthotopic) (5) (5,10,and 15)
MDA-MB-231 120 mm2 1/5
(orthotopic) (5) (7)
MDA-MB-231 20-120 mm2 0/20
(subcutaneous) (20)
KPL-4 50 mm2 0/3
(orthotopic) (3)
KPL-4 80 mm2 1/2
(orthotopic) (2) (20)
KPL-4 120 mm2 1/4
(orthotopic) (4) (15)
CTCs could be quantified by qRT-PCR targeting human Alu-sequences in 6 out
of 29 blood samples gained from xenografted animals. CTCs were detectable
at tumour sizes between 80 to 140 mm2 (MDA-MB-231 and KPL-4). No CTCs
could be detected in a subcutaneous MDA-MB-231 model. Number of CTCs
were calculated by spiking rows which were included in every run.
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taken by cardiac puncture. Again, down-regulation of
epithelial EpCAM and MUC-1 was observed, whereas
transcripts of the mesenchymal marker vimentin and
the house-keeping genes were detected in 100% of the
blood samples (Figure 6c).
A more detailed comparative analysis of KPL-4 cells
taken from cell culture and circulating KPL-4 cells in
blood from tumour-bearing mice revealed changes in ex-
pression of EMT-associated genes with upregulation of
Twist, Collagen-alpha-2(V)-chain (COL5A2), epidermal
growth factor receptor (EGFR), moesin (MSN) and beta-
type platelet-derived growth factor receptor (PDGFRB)
in the latter. In contrast, expression of epithelial markers
like cytokeratin-19 (CK-19) and osteopontin (SPP1) was
slightly reduced in CTCs (Figure 7).
Discussion
We confirm here previous reports that the AdnaTest is a
very sensitive assay for detection of epithelial cells. We also
demonstrate that the sensitivity of the assay was signifi-
cantly dependent on the expression levels of EpCAM,
which was causally linked to its failure to detect any posi-
tive CTC sample in murine breast cancer xenograft mod-
els. We were able to show that EMT occurs in vivo during
formation of metastases in tumour-bearing mice. Thesechanges include the down-regulation of EpCAM. We
showed for the first time that gene expression changes in
CTCs are very fast and seem to depend on contact with
endothelial surfaces or organ systems in vivo, since even
i.v. injected tumour cells quickly down-regulated EpCAM.
The surprisingly fast loss of EpCAM could be explained by
cleavage and shedding of the extracellular domain as
described [15,16]. Besides the down-regulation of EpCAM,
we identified up-regulation of mesenchymal markers like
COL5A2, EGFR, MSN, PDGFRB and Twist in CTCs, sup-
porting the epithelial-to-mesenchymal transition as the
cause for down-regulation of EpCAM. Confirming our
findings, COL52A has been identified as marker for EMT,
since TGFβ/TNFα-treatment induced a mesenchymal cell
phenotype accompanied with increased expression of this
gene [17]. EGF signaling has also been previously linked to
tumour progression and metastasis [18-21]. We found dra-
matically increased EGFR expression in CTCs, confirming
the role of this pathway in the process of metastatic spread.
It has been shown that EGF can induce EMT-like effects
including upregulation of Twist through the EGFR path-
way [22]. Twist expression has been described as a crucial
regulator of EMTand metastasis formation [23]. CTCs also
showed elevated Twist expression levels in our model, con-
firming these findings [23]. The modified gene expression
profile that we report here could provide the basis for alter-
native methods for isolation and detection of CTCs from
clinical samples. The surface marker EGFR may be useful
for capturing mesenchymal-like CTC subpopulations,
whereas the intracellular proteins like vimentin, collagen-
alpha-2 and Twist could be used for improved detection of
CTCs by immunostaining. Such approaches will be espe-
cially useful to confirm the identity of CTC populations
isolated by size exclusion as recently described [24]. The
isolation of CTCs based on their size is independent of epi-
thelial marker expression and therefore leads to higher
CTC yields. A larger set of tumor-specific markers will be
useful in confirming the identity of CTC populations
enriched by filtration methods.
In contrast to this study, CTC detection has previously
been described using an EpCAM-based method in a
murine xenograft model [9]. In addition, CTC-positive
samples were found in murine prostate cancer xeno-
grafts using a CTC-chip [10], which has been previously
described and evaluated [25]. Either EpCAM expression
was not downregulated in the PC3 model or the CTC
chip captures even cells with very little residual EpCAM
expression. This hypothesis is supported by the fact that
low EpCAM cells are captured late on the CTC-chip
whereas cells with high EpCAM expression are bound
already in the beginning of the flowpath (pers. commu-
nication S. Nagrath). Down-regulation of MUC-1 and
Her2 on CTCs has also been noted by this group, in
keeping with our findings. More recently, increased
Figure 6 (See legend on next page)
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Figure 6 a. Detection of spiked KPL-4 cells and cells after i.v. injection. 10 cells were spiked into 100 μl or 1 ml of native murine blood
samples. Cells of the KPL-4 line stably expressed EpCAM, Her2 and the housekeeping-genes for up to 4 h. The cells could be detected by
AdnaTest and without antibody enrichment (a.). 100,000 cells of the KPL-4 cell line were injected into the tail vein of native mice. Tumour cells
could not be detected by the AdnaTest, whereas human mRNA was visible without antibody enrichment for up to 4 h after injection. The
detected cells showed serial changes and reduced EpCAM expression already 30 min after i.v. injection (b.). b. Tissue analyses for human
mRNA after injection of 100,000 KPL-4 cells into the tail vein. Tissues were homogenised and RNA was purified followed by cDNA synthesis
and PCR reaction. Human breast cancer cells detectable in the lungs and one liver were positive for EpCAM and Her2 expression up to 2 h after
KPL-4 cell injection. c. MDA-MB-231 breast cancer cells were injected into the heart and blood was analysed for human mRNA signals.
CTCs were detectable in all animals for up to 5 h after injection. The detected cells showed changes of mRNA expression including
downregulation of EpCAM and MUC-1, whereas mRNA of the housekeeping-genes and mesenchymal Vimentin was visible permanently.
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CTCs in another orthotopic breast cancer model, has
been published [26]. Taken together, these results dem-
onstrate that phenotypic changes occur in CTCs. For
this reason, we believe that new methods are needed to
ensure that the complete phenotypic variability of CTC
populations can be described.
Although the prognostic value of CTC counts have
been demonstrated using epithelial marker based CTC
detection methods [27-30], our findings indicate that nu-
merous cells may be lost in many blood samples of can-
cer patients due to EMT processes. This may explain
why even in late stage metastatic patients, only around
50% of the patients with breast or prostate cancer have
more than 5 CTCs and in case of colorectal cancer only
26% more than 3 CTCs in 7.5 ml blood. Other authors
failed to detect subtypes of CTCs resembling normal
type breast cancer using the CellSearch technique [31].
Further, significantly higher numbers of CTCs could be
detected using an EpCAM independent detection
method compared to EpCAM based enrichmentFigure 7 Profile changes of in vitro KPL-4 cells compared to
circulating KPL-4 cells out of tumour bearing animals. Samples
were analysed using RT2 Profiler PCR Array System focusing on EMT
specific genes. Data analyses shows that COL5A2, EGFR, MSN,
PDGFRB and Twist were upregulated on CTCs whereas
downregulation of CK-19 and SPP1 could be observed (n = 5).technology (69.2% vs. 42.3%) in breast cancer patients
[32], suggesting that a mixture of EpCAM positive and
EpCAM negative tumour cells circulate in the blood. In
a study of neuroendocrine cancer patients using Cell-
Search, CTCs were found in only 21-43% of the patients,
although 100% of the tumours showed strong membrane
EpCAM expression by IHC [33]. Down-regulation of
EpCAM has been reported independently for DTCs in
bone marrow and CTCs in peripheral blood of patients
with breast cancer and for other solid tumors [34,35].
These publications demonstrate that the use of anti-
EpCAM antibody-based enrichment strategies limits the
clinical utility the CellSearch System, the AdnaTest or
other EpCAM based procedures. Our own data and sev-
eral recent studies support the hypothesis that EMT-like
shifts on CTCs occur during metastatic spread [5-7,36].
These results indicate that CTCs will be lost using
immuno-affinity enrichment that relies only on the level
of EpCAM expression on the cell surface [37].
Taken together, our findings explain low CTC num-
bers in clinical studies even in metastatic cancer. The
use of EpCAM-based enrichment techniques leads to
the selective loss of CTC populations undergoing
epithelial-to-mesenchymal transition. We could show
that new technologies have to be developed which se-
curely isolate all CTCs. Methods for the analysis of
CTCs in clinical samples should be designed to detect
both epithelial and mesenchymal-like subpopulations.
Our findings could be used as a starting point for the
qualification of new markers for CTC detection or cap-
ture including the mesenchymal-like subpopulations. Fu-
ture studies should consider the heterogeneity of CTC
populations and find out which one is prognostic for the
course of the disease and which population may give
best hints towards therapeutic options.
Conclusion
As we have shown in this work, the use of single surface
markers for isolation of CTCs can lead to the loss of
CTC populations having undergone phenotypic changes
like the epithelial to mesenchymal transition. This find-
ing may explain the clinical results with low CTC counts
or even absence of detectable CTCs in many even late
Gorges et al. BMC Cancer 2012, 12:178 Page 12 of 13
http://www.biomedcentral.com/1471-2407/12/178metastatic cancer patients. Future research has to iden-
tify new selection markers that are robustly expressed
and not subject to phenotypic changes. An alternative is
the enrichment of CTCs based on size and a detailed
molecular analysis of the enriched cell population espe-
cially in respect to predictive markers like target expres-
sion and/or specific mutations.
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